Fish Oil and HRV: Why a Slower Pulse Isn’t Better Vagal Tone

Fish oil may slow your resting pulse, but current controlled evidence does not show that it reliably improves heart rate variability (HRV). Those outcomes often travel together in wellness marketing, yet they measure different things: heart rate is the number of beats per minute; HRV describes variation in the timing between beats and can reflect cardiac autonomic regulation.

The distinction matters if HRV or "vagal tone" is your target. A 2026 systematic review pooling four randomized trials, with 134 participants total, found no statistically significant placebo-controlled differences in frequency-domain HRV measures: high-frequency (HF) power, low-frequency (LF) power, or the LF/HF ratio. The review included only 90 participants assigned to omega-3 and 44 controls, so it cannot rule out a modest benefit. It does rule out treating HRV improvement as an established fish-oil effect.

The best pooled answer is null, not definitive

Ibrahim et al.'s 2026 systematic review examined four randomized controlled trials published between 2008 and 2025, largely in overweight or obese populations. In the placebo-controlled pooled analysis, omega-3 supplementation did not significantly outperform control for HF power, LF power, or LF/HF ratio. HF power is commonly used as an index of parasympathetic, or vagal, cardiac activity, which makes that null result especially relevant to claims that fish oil raises vagal tone.

The review does not settle the question forever. Four small trials totaling 134 people leave plenty of room for uncertainty, particularly for small-to-moderate effects. The publication does not provide a usable dose-response picture across all four trials: dose, duration, and EPA-to-DHA composition were not recoverable for three of them. One of the four trials also carried a high overall risk-of-bias rating under Cochrane ROB 2.0. With fewer than 10 studies per outcome, the authors could not assess publication bias with funnel plots.

Still, "underpowered" does not mean "positive until proven otherwise." It means the honest conclusion is narrower: existing placebo-controlled evidence has not found a consistent HRV benefit.

One high-dose DHA trial did find a signal

The main reason fish oil retains an HRV reputation is a real, but isolated, positive study. In the 2008 Ninio trial included in the review, 50 sedentary Australian adults with overweight took 6 g per day of DHA-dominant fish oil for 12 weeks. The intervention supplied about 1,560 mg DHA and 360 mg EPA daily, a DHA-to-EPA ratio of roughly 4.3:1. Participants received sunflower oil as the placebo comparator.

That trial found a significant increase in HF power and a significant reduction in resting heart rate versus placebo. It had a low risk-of-bias rating, which makes it more informative than a casual before-and-after supplement experiment. But its result did not persist when the review pooled the available placebo-controlled frequency-domain data. A 12-week, 6 g-per-day, strongly DHA-weighted protocol is also far from a typical over-the-counter fish-oil routine.

Several explanations remain possible: the response could depend on that unusual formulation and dose, on characteristics of that sedentary overweight cohort, or on chance. The current evidence cannot choose among them. No randomized trial in this set directly compared EPA-dominant with DHA-dominant products for HRV, so claims that one formulation reliably "fixes" autonomic function get ahead of the data.

Why before-and-after HRV improvements can mislead

The review reported apparent pre-to-post improvements in time-domain measures such as RMSSD, SDNN, and pNN50 in omega-3 groups. Those numbers should not be read as proof of a treatment effect. Two of the four trials used participants' own pre-intervention measurements as the control condition for these analyses rather than a parallel placebo group.

HRV changes with factors that can shift between testing days: recent exercise, caffeine, sleep, ambient conditions, and habituation to measurement. For example, a 2022 systematic review of caffeine before exercise found that caffeine affected post-exercise HRV recovery in healthy active adults. That does not test fish oil, but it illustrates why HRV studies need tightly standardized conditions and placebo comparisons. Regression to the mean can also make an initially low reading look better on retest. The placebo-controlled frequency-domain analysis is therefore the more dependable signal here, and it was null.

A slower heart rate is a separate finding

The cleanest counterweight to the HRV claim comes from healthy adults. In a randomized trial, Macartney et al. in 2022 gave non-obese adults DHA-rich fish oil. Their omega-3 index increased, confirming that the fatty acids were incorporated into tissue. Resting heart rate fell significantly, but measures of cardiac autonomic reflex modulation did not change.

That pairing is useful because it separates exposure from outcome. The supplement reached its biological target and changed resting pulse, yet it did not alter the HRV-related autonomic endpoints measured in the study. It also weakens the idea that fish oil fails only because overweight adults have impaired autonomic reserve. The HRV-null pattern appeared in healthy, lean adults as well.

The mechanism for heart-rate slowing may involve direct effects on sinoatrial-node membrane dynamics rather than a change in autonomic nervous-system control. That remains a mechanistic interpretation, not proof that every product or dose will lower pulse. The practical point is simpler: a lower resting heart rate does not demonstrate higher HRV.

Association in dialysis patients does not answer the supplement question

A 2021 cross-sectional pilot study by Pinto et al. adds biological context but not causal evidence. The study examined 45 adults with stage 5 chronic kidney disease who had recently started hemodialysis. It related circulating and erythrocyte long-chain omega-3 measures to 24-hour HRV measures in a population with severe illness and dialysis-related autonomic disruption.

Such associations cannot show that raising omega-3 intake will improve HRV. The study did not randomly assign fish oil, and the participants' kidney disease, fluid shifts, medications, and dialysis exposure make them a poor stand-in for generally healthy people taking a capsule with breakfast. In fact, the study's adjusted findings were not a simple endorsement of the usual omega-3-index story: mean erythrocyte omega-3 index was not associated with HRV after adjustment for age, BMI, and beta-blocker use.

What to do if HRV is the goal

Do not buy fish oil primarily to raise HRV or vagal tone. The best available synthesis found no significant placebo-controlled improvement in frequency-domain HRV across four small trials, and the one positive 12-week study has not replicated in the pooled evidence. Measuring a lower pulse after starting fish oil does not change that conclusion.

Fish oil can still have cardiovascular uses that rest on other evidence streams, including triglyceride lowering and condition-specific clinical indications. Those questions require their own evidence and, for people with cardiovascular disease, arrhythmia, anticoagulant use, or planned high-dose supplementation, a clinician's advice. HRV is a measurement-sensitive surrogate marker, not a report card on whether a supplement is "working."

Current evidence supports a modestly cautious verdict: DHA-rich fish oil can slow resting heart rate, but fish oil has not shown a reliable placebo-controlled effect on HRV in overweight or healthy adults.

For the underlying trial details and pooled HRV analysis, see the 2026 review. Its limitations are also the research agenda: larger, standardized placebo-controlled trials, with predefined HRV protocols and direct EPA-versus-DHA comparisons, are needed before anyone can make a credible formulation-specific HRV claim.